Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BA.5.1.12ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.5.1.12NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.5.1.12NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BF.11.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BF.11.2NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BF.11.2NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
EE.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
EE.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
EE.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-21956.6US
BN.3.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-20394.2Germany
BN.3.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BN.3.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BE.4.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BE.4.2NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BE.4.2NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-21956.6US
BY.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BY.1NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BY.1NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.5.2.3ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.5.2.3NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.5.2.3NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.36ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BA.2.36NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.36NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BE.1.1.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BE.1.1.2NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BE.1.1.2NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-21956.6US
BN.1.5ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BN.1.5NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BN.1.5NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BF.7ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BF.7NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BF.7NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.23ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.23NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.23NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.5.2.44ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.5.2.44NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.5.2.44NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BN.1.3.9ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BN.1.3.9NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BN.1.3.9NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BQ.1.1.8ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BQ.1.1.8NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BQ.1.1.8NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-21956.6US
DV.6ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
DV.6NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
DV.6NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2 (Omicron)ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2 (Omicron)NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-4914.61China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used